Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study

Thomas E. Hutson,Joaquim Bellmunt,Camillo Porta,Michael Staehler,Cezary Szczylik,Allan S. Nadel,Sibyl Anderson,Ronald M. Bukowski,T. Eisen,B. Escudier

Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study

2009

Thomas E. Hutson
Joaquim Bellmunt
Camillo Porta
Michael Staehler
Cezary Szczylik
Allan S. Nadel
Sibyl Anderson
Ronald M. Bukowski
T. Eisen
B. Escudier

e16057 Background: Results of the phase III multicenter TARGET study, a randomized, double-blind, placebo (PBO)- controlled study of tx with SOR in pts with clear-cell RCC in whom 1 prior systemic ...

Keywords:

Sorafenib
Cancer research
Clear cell renal cell carcinoma
Medicine
long term safety
Oncology
Placebo
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations